Compounds > lofepramine hydrochloride
Page last updated: 2024-08-23

lofepramine hydrochloride and Disease Models, Animal

lofepramine hydrochloride has been researched along with Disease Models, Animal in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's0 (0.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV1
Bohme, GA; Boireau, A; Damour, D; Debono, MW; Genevois-Borella, A; Jimonet, P; Mignani, S; Pratt, J; Randle, JC; Ribeill, Y; Stutzmann, JM; Vuilhorgne, M1
Bohme, GA; Boireau, A; Bouquerel, J; Damour, D; Debono, MW; Genevois-Borella, A; Hardy, JC; Hubert, P; Jimonet, P; Manfré, F; Mignani, S; Nemecek, P; Pratt, J; Randle, JC; Ribeill, Y; Stutzmann, JM; Vuilhorgne, M1
Anraku, T; Asano, J; Hori, W; Shiga, F; Takano, Y; Uno, T1

Other Studies

4 other study(ies) available for lofepramine hydrochloride and Disease Models, Animal

ArticleYear
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49

    Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection

2020
Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden.
    Bioorganic & medicinal chemistry letters, 2000, Dec-18, Volume: 10, Issue:24

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Brain; Cell Membrane; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Excitatory Amino Acid Agonists; Heterocyclic Compounds, 4 or More Rings; Imidazoles; Inhibitory Concentration 50; Male; Mice; Mice, Inbred DBA; Oocytes; Protein Binding; Pyrazines; Rats; Receptors, AMPA; Seizures; Structure-Activity Relationship; Time Factors; Xenopus

2000
Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action.
    Bioorganic & medicinal chemistry letters, 2001, Jan-22, Volume: 11, Issue:2

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Combinatorial Chemistry Techniques; Disease Models, Animal; Excitatory Amino Acid Antagonists; Imidazoles; Inhibitory Concentration 50; Male; Mice; Oocytes; Pyrazinamide; Pyrazines; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Seizures; Structure-Activity Relationship

2001
Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl group and improved its good physicochemical properties by introduced CF3 group.
    Bioorganic & medicinal chemistry letters, 2004, Oct-18, Volume: 14, Issue:20

    Topics: Animals; Brain Ischemia; Disease Models, Animal; Imidazoles; In Vitro Techniques; Infusions, Intravenous; Neuroprotective Agents; Quinoxalines; Rats; Receptors, AMPA; Solubility; Structure-Activity Relationship

2004